Leadership Changes at Hesperos, Inc.
Hesperos, Inc., known for its groundbreaking Human-on-a-Chip technology, has appointed Lawrence (Larry) Florin as its new Chief Executive Officer. With over 20 years of experience in the biomedical and clinical technology fields, Mr. Florin’s leadership is expected to drive significant growth and innovation within the company.
A Proven Track Record
Before taking on the role at Hesperos, Larry Florin was Chief Clinical Officer at Immunicom, Inc., where he led various initiatives in the immuno-oncology sector. His extensive background also includes serving as a strategic advisor for several biopharma and clinical research organizations, positioning him as a key figure in enhancing drug development.
Focus on Growth and Innovation
J. Hickman, PhD, Co-founder and Chief Scientist at Hesperos, expressed excitement over Mr. Florin’s appointment, highlighting the alignment of his clinical expertise with the company's mission. The goal is to hasten the development of safer and more effective therapies, reflecting the dynamic nature of the bio-pharmaceutical industry.
Noteworthy Contributions
In his career, Larry has successfully led fundraising efforts that have raised over $120 million. His leadership will be critical during this era of rapid growth in the microphysiological systems (MPS) field. Mr. Florin's commitment to innovation ensures that Hesperos remains at the forefront of drug discovery and development.
A Vision for the Future
Mr. Florin has previously stated his enthusiasm to lead Hesperos into what he describes as a period of explosive growth. His vision includes continuing to refine the Human-on-a-Chip technology, which offers invaluable insights into therapeutic profiles and enhances clinical trial efficiencies.
Academic and Professional Background
He holds a BS in biology from Ursinus College and an Executive MBA from Temple University. As a frequent speaker at industry events, he is recognized for his innovative approaches to patient recruitment and clinical development enhancement.
About Hesperos, Inc.
Hesperos, Inc. is a distinguished global contract research organization focused on advancing preclinical drug development through its Human-on-a-Chip platform. This innovative platform not only replicates human biological responses but also aims to reduce reliance on animal testing, providing more accurate predictions of therapeutic effects and boosting development efficiency.
Frequently Asked Questions
Who is the new CEO of Hesperos, Inc.?
The new CEO of Hesperos, Inc. is Lawrence (Larry) Florin, who has extensive experience in the biotech industry.
What is the Human-on-a-Chip technology?
The Human-on-a-Chip technology is a pioneering method that simulates human biology for drug development, aiming to improve preclinical testing outcomes.
What are Larry Florin's qualifications?
Larry Florin holds a biology degree and an Executive MBA, with over two decades of leadership in the clinical technology field.
What is Hesperos, Inc.'s mission?
Hesperos aims to accelerate the development of safer and more effective therapeutics through innovative technologies and processes in drug discovery.
How does Hesperos impact drug development?
By employing its Human-on-a-Chip platform, Hesperos provides more meaningful insights that help predict therapeutic efficacy while reducing costs and timelines.
